Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Blood (2023) 142 (Supplement 1): 2913.

https://doi.org/10.1182/blood-2023-186620

Published: 2023

Journal Articles

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud, Sr., Jan Maciej Zaucha, Scott R. Solomon, Terrence Bradley, Elie Mouhayar, Noemi Angelosanto, Hendrik Nogai, Renata Dudziak, Tomasz Rzymski, Peter Littlewood, Krzysztof Brzózka, Axel Glasmacher, Gautam Borthakur, Howard A. Burris, Sr., Ewa Lech Marańda

Blood (2022) 140 (Supplement 1): 6228–6229.

https://doi.org/10.1182/blood-2022-163150

Published: 2022

Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Blood (2021) 138 (Supplement 1): 2371.

https://doi.org/10.1182/blood-2021-152273

Published: 2021

Journal Articles

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Camille Abboud, Sr., Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Sr., Terrence Bradley, JAN Maciej Zaucha, Sr., Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto

Blood (2021) 138 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2021-151030

Published: 2021

Journal Articles

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Wolfram Brugger, MDPhD, Susan Ashton, Carrie A. Adelman, Nicolas Floc'h, Paula Taylor, Maureen Hattersley, PhD, Shenghua Wen, Kimberly Maratea, Philip Overend, Steven Fox, Julie Charlton, Simon T Barry, Donald Strickland, MD, Suzanne Jones, PharmD, Howard A. Burris, MD, Carol Greenlees, Alexander MacDonald, J. Elizabeth Pease, PhD, William Donnellan

Blood (2017) 130 (Supplement 1): 1368.

https://doi.org/10.1182/blood.V130.Suppl_1.1368.1368

Published: 2017

Journal Articles

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

Jason Kaplan, MD, Leo I. Gordon, MD, Alessandro Rambaldi, MD Prof, Giuseppe Gritti, MD, Rakesh Popat, MD PhD, Howard A. Burris, MD, Manish R Patel, MD, Sumit Madan, MD, Ian Chau, MD, John A. Radford, MD, Swami P. Iyer, MD, Jaime Perez De Oteyza, MD, Pier Luigi Zinzani, MD, Shining Wang, MD, Emily Sheldon-Waniga, PhD, Kate Stumpo, BA, Yaping Shou, MD PhD, Cecilia Carpio, MD, Francesc Bosch, MD

Blood (2017) 130 (Supplement 1): 1554.

https://doi.org/10.1182/blood.V130.Suppl_1.1554.1554

Published: 2017

Journal Articles

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O'Connor, MD, Ian W. Flinn, MD PhD, Manish R. Patel, MD, Timothy S. Fenske, MD, Changchun Deng, MD PhD, Danielle M. Brander, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John G Kuhn, Pharm.D., Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Howard A. Burris, III, MD

Blood (2015) 126 (23): 4154.

https://doi.org/10.1182/blood.V126.23.4154.4154

Published: 2015

Journal Articles

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Howard A. Burris, MD, Manish R. Patel, MD, Danielle M. Brander, MD, Owen A. O'Connor, MD PhD, Changchun Deng, MD PhD, Timothy S. Fenske, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John Kuhn, PharmD, Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Ian Flinn

Blood (2014) 124 (21): 1984.

https://doi.org/10.1182/blood.V124.21.1984.1984

Published: 2014

Journal Articles

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

C.J. Godfrey, PhD, Christopher H. Cabell, MD, MHS, FACC, Barbara Balser, VMD, Julie Wolfson, MPH, Jean Nichols, PhD, Howard A. Burris, III, MD

Blood (2011) 118 (21): 2680.

https://doi.org/10.1182/blood.V118.21.2680.2680

Published: 2011

Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 4015.

https://doi.org/10.1182/blood.V116.21.4015.4015

Published: 2010

Journal Articles

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Ian W. Flinn, MD, PhD, Jesus G. Berdeja, MD, Jamie K. Waselenko, MD, R. Seth Cooper, MD, Jia Bi, MD, Kent Shih, MD, Habib H. Doss, MD, Natalie Dickson, MD, Dana S. Thompson, MD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 2461.

https://doi.org/10.1182/blood.V116.21.2461.2461

Published: 2010

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

John D. Hainsworth, Howard A. Burris, III, Lisa H. Morrissey, Sharlene Litchy, Daniel C. Scullin, Jr, James D. Bearden, III, Paul Richards, F. Anthony Greco

Blood (2000) 95 (10): 3052–3056.

https://doi.org/10.1182/blood.V95.10.3052

Published: 2000

NARROW

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only